447 related articles for article (PubMed ID: 17876741)
21. Natalizumab in the treatment of patients with multiple sclerosis: first experience.
Mareckova H; Havrdova E; Krasulova E; Vankova Z; Koberová M; Sterzl I
Ann N Y Acad Sci; 2007 Sep; 1110():465-73. PubMed ID: 17911462
[TBL] [Abstract][Full Text] [Related]
22. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
Mult Scler; 2011 Jun; 17(6):708-19. PubMed ID: 21228027
[TBL] [Abstract][Full Text] [Related]
23. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
Balcer LJ; Galetta SL; Calabresi PA; Confavreux C; Giovannoni G; Havrdova E; Hutchinson M; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA
Neurology; 2007 Apr; 68(16):1299-304. PubMed ID: 17438220
[TBL] [Abstract][Full Text] [Related]
24. Review of progressive multifocal leukoencephalopathy and natalizumab.
Aksamit AJ
Neurologist; 2006 Nov; 12(6):293-8. PubMed ID: 17122725
[TBL] [Abstract][Full Text] [Related]
25. [Natalizumab (Tysabri)].
Ravnborg M
Ugeskr Laeger; 2007 Sep; 169(38):3184-7. PubMed ID: 17910826
[TBL] [Abstract][Full Text] [Related]
26. Reactivation of JC virus and development of PML in patients with multiple sclerosis.
Khalili K; White MK; Lublin F; Ferrante P; Berger JR
Neurology; 2007 Mar; 68(13):985-90. PubMed ID: 17389301
[TBL] [Abstract][Full Text] [Related]
27. Multiple sclerosis: interferon beta for some serious forms.
Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
[TBL] [Abstract][Full Text] [Related]
28. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
Keeley KA; Rivey MP; Allington DR
Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
[TBL] [Abstract][Full Text] [Related]
29. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
30. Natalizumab treatment in pediatric multiple sclerosis: a case report.
Borriello G; Prosperini L; Luchetti A; Pozzilli C
Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
[TBL] [Abstract][Full Text] [Related]
31. [Monoclonal antibodies in multiple sclerosis].
Papeix C; Lubetzki C
Med Sci (Paris); 2009 Dec; 25(12):1113-5. PubMed ID: 20035688
[TBL] [Abstract][Full Text] [Related]
32. Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.
Wenning W; Haghikia A; Laubenberger J; Clifford DB; Behrens PF; Chan A; Gold R
N Engl J Med; 2009 Sep; 361(11):1075-80. PubMed ID: 19741228
[TBL] [Abstract][Full Text] [Related]
33. [Current treatment of multiple sclerosis].
Csépány T
Lege Artis Med; 2011 Feb; 21(2):97-104. PubMed ID: 21710707
[TBL] [Abstract][Full Text] [Related]
34. Multiple sclerosis and Natalizumab.
Fiore D
Am J Ther; 2007; 14(6):555-60. PubMed ID: 18090880
[TBL] [Abstract][Full Text] [Related]
35. Clinical evaluation of natalizumab for formulary consideration.
Bivins A; Hou K; Ayesu N; Ellsworth B; Montenegro S; Tu X; Boyle C; Dowling T; Shaya FT
Expert Opin Biol Ther; 2010 Aug; 10(8):1279-87. PubMed ID: 20626228
[TBL] [Abstract][Full Text] [Related]
36. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis.
Horga A; Castillo J; Rio J; Tintore M; Auger C; Sastre-Garriga J; Edo MC; Perez-Miralles F; Tur C; Nos C; Huerga E; Comabella M; Rovira A; Montalban X
Rev Neurol; 2011 Mar; 52(6):321-30. PubMed ID: 21387248
[TBL] [Abstract][Full Text] [Related]
37. [New drugs; natalizumab].
van Bronswijk H; Dubois EA; van Gerven JM; Cohen AF
Ned Tijdschr Geneeskd; 2008 Mar; 152(9):499-500. PubMed ID: 18389881
[TBL] [Abstract][Full Text] [Related]
38. Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosis.
Dorsey ER; Thompson JP; Noyes K; Dick AW; Holloway RG; Schwid SR
Neurology; 2007 May; 68(18):1524-8. PubMed ID: 17470756
[TBL] [Abstract][Full Text] [Related]
39. Treating multiple sclerosis in the natalizumab era: risks, benefits, clinical decision making, and a comparison between North American and European Union practices.
Giovannoni G; Kinkel P; Vartanian T
Rev Neurol Dis; 2007; 4(4):184-93. PubMed ID: 18195670
[TBL] [Abstract][Full Text] [Related]
40. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
O'Connor PW; Goodman A; Kappos L; Lublin FD; Miller DH; Polman C; Rudick RA; Aschenbach W; Lucas N
Neurology; 2011 May; 76(22):1858-65. PubMed ID: 21543733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
